Another study finds that cannabinoids, like those found in marijuana, suppress the pain resulting from chemotherapy-induced neuropathy. And the Feds continue to claim that there is no medical use for marijuana. J Pain Symptom Manage. 2013 Jun 4. pii: S0885-39241300238-8. doi: 10.1016/j.jpainsymman.2013.02.018. [Epub ahead of print]A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced Neuropathic Pain.Lynch ME, Cesar-Rittenberg P, Hohmann AG.SourcePain Management Unit, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Anesthesia, Psychiatry and Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada. Electronic address: email@example.com. Abstract: Neuropathic pain caused by chemotherapy limits dosing and duration of potentially life-saving anti-cancer treatment and impairs quality of life. Chemotherapeutic neuropathy responds poorly to conventional treatments, and there is an urgent medical need for new treatments. Recent preclinical studies demonstrate that cannabinoid agonists suppress established chemotherapy-evoked neuropathy.OBJECTIVES:This was a pilot trial to begin to investigate a currently available cannabinoid agent, nabiximols oral mucosal spray containing cannabinoids, in the treatment of chemotherapy-induced neuropathic pain.METHODS:A randomized, placebo-controlled crossover pilot study was done in 16 patients with established chemotherapy-induced neuropathic pain. A 0-10 point numeric rating scale for pain intensity NRS-PI was used as the primary outcome measure.RESULTS:When examining the whole group, there was no statistically significant difference between the treatment and the placebo groups on the NRS-PI. A responder analysis demonstrated that there were five participants who reported a two-point or greater reduction in pain that trended toward statistical significance and the number needed to treat was five.CONCLUSION:Chemotherapy-induced neuropathic pain is particularly resistant to currently available treatments. This pilot trial found a number needed to treat of five and an average decrease of 2.6 on an 11-point NRS-PI in five "responders" as compared with a decrease of 0.6 with placebo and supports that it is worthwhile to study nabiximols in a full randomized, placebo-controlled trial of chemotherapy-induced neuropathic pain.
This is an important study because it shows that the naturally-occurring cannabinoid molecule THC was safer, and more effective against cancer cells than was a synthetic cannabinoid, WIN 55,212-2. Yet researchers are discouraged from using cannabinoids from marijuana in lieu of the synthetic ones, because good findings about THC might "send the wrong message to young people." So now young people are getting a hold of far more dangerous synthetic cannabinoids and using them recreationally...the Law of Unintended Consequences. Neurooncol. 2005 Aug;741:31-40.Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.McAllister SD, Chan C, Taft RJ, Luu T, Abood ME, Moore DH, Aldape K, Yount G. Abstract: Normal tissue toxicity limits the efficacy of current treatment modalities for glioblastoma multiforme GBM. We evaluated the influence of cannabinoids on cell proliferation, death, and morphology of human GBM cell lines and in primary human glial cultures, the normal cells from which GBM tumors arise. The influence of a plant derived cannabinoid agonist, Delta9-tetrahydrocannabinol Delta9-THC, and a potent synthetic cannabinoid agonist, WIN 55,212-2, were compared using time lapse microscopy. We discovered that Delta9-THC decreases cell proliferation and increases cell death of human GBM cells more rapidly than WIN 55,212-2. Delta9-THC was also more potent at inhibiting the proliferation of GBM cells compared to WIN 55,212-2. The effects of Delta9-THC and WIN 55,212-2 on the GBM cells were partially the result of cannabinoid receptor activation. The same concentration of Delta9-THC that significantly inhibits proliferation and increases death of human GBM cells has no significant impact on human primary glial cultures. Evidence of selective efficacy with WIN 55,212-2 was also observed but the selectivity was less profound, and the synthetic agonist produced a greater disruption of normal cell morphology compared to Delta9-THC.PMID: 16078104 [PubMed - indexed for MEDLINE]
THC from marijuana is a safe, effective and thoroughly enjoyable cannabinoid receptor agonist. Best Pract Res Clin Endocrinol Metab. 2009 Feb; Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Pisanti S, Malfitano AM, Grimaldi C, Santoro A, Gazzerro P, Laezza C, Bifulco M.Source Department of Pharmaceutical Sciences, University of Salerno, Italy. Abstract: Cannabinoids the active components of Cannabis sativa and their derivatives have received renewed interest in recent years due to their diverse pharmacological activities. In particular, cannabinoids offer potential applications as anti-tumour drugs, based on the ability of some members of this class of compounds to limit cell proliferation and to induce tumour-selective cell death. Although synthetic cannabinoids may have pro-tumour effects in vivo due to their immunosuppressive properties, predominantly inhibitory effects on tumour growth and migration, angiogenesis, metastasis, and also inflammation have been described. Emerging evidence suggests that agonists of cannabinoid receptors expressed by tumour cells may offer a novel strategy to treat cancer. In this chapter we review the more recent results generating interest in the field of cannabinoids and cancer, and provide novel suggestions for the development, exploration and use of cannabinoid agonists for cancer therapy, not only as palliative but also as curative drugs.PMID: 19285265 [PubMed - indexed for MEDLINE]
Marijuana fights beast cancer, why wait for "officials" to approve it? Use it now! Family history of breast cancer? Use it now! History of poor diet and alcohol consumption? Use it now! Cancer Treat Rev. 2012 Nov;10. 2012
Cannabinoids: a new hope for breast cancer therapy? Caffarel MM, et al., Dept. Biochemistry and Molecular Biology I, School of Biology, Complutense University-CIBERNED-IRYCIS, Madrid, Spain. Abstract: Breast cancer is a very common disease that affects approximately 1 in 10 women at some point in their lives. Importantly, breast cancer cannot be considered a single disease as it is characterized by distinct pathological and molecular subtypes that are treated with different therapies and have diverse clinical outcomes. Although some highly successful treatments have been developed, certain breast tumors are resistant to conventional therapies and a considerable number of them relapse. Therefore, new strategies are urgently needed, and the challenge for the future will most likely be the development of individualized therapies that specifically target each patient's tumor. Experimental evidence accumulated during the last decade supports that cannabinoids, the active components of Cannabis sativa and their derivatives, possess anticancer activity. Thus, these compounds exert anti-proliferative, pro-apoptotic, anti-migratory and anti-invasive actions in a wide spectrum of cancer cells in culture. Moreover, tumor growth, angiogenesis and metastasis are hampered by cannabinoids in xenograft-based and genetically-engineered mouse models of cancer. This review summarizes our current knowledge on the anti-tumor potential of cannabinoids in breast cancer, which suggests that cannabinoid-based medicines may be useful for the treatment of most breast tumor subtypes.Copyright © 2012 Elsevier Ltd. All rights reserved.
PerspectivesNature Reviews Cancer 12, 436-444 June 2012 | doi:10.1038/nrc3247 Opinion: Towards the use of cannabinoids as antitumour agents Guillermo Velasco1,2,3, Cristina Sánchez1 & Manuel Guzmán1,2,4 Various reports have shown that cannabinoids the active components of marijuana and their derivatives can reduce tumour growth and progression in animal models of cancer, in addition to their well-known palliative effects on some cancer-associated symptoms. This Opinion article discusses our current understanding of cannabinoids as antitumour agents, focusing on recent insights into the molecular mechanisms of action, including emerging resistance mechanisms and opportunities for combination therapy approaches. Such knowledge is required for the optimization of preclinical cannabinoid-based therapies and for the preliminary clinical testing that is currently underway.
US Investigators Praise Cannabinoids As Chemo Treatment“ Cannabinoids inhibit cancer cell proliferation and should be clinically tested as chemotherapeutic agents, according to a review published in the January issue of the journal Cancer Research.Investigators at the University of Wisconsin School of Medicine and Public Health reported that the administration of cannabinoids halts the spread of a wide range of cancers, including brain cancer, prostate cancer, breast cancer, lung cancer, skin cancer, pancreatic cancer, and lymphoma. Researchers suggested that cannabinoids may offer significant advantages over standard chemotherapy treatments because the compounds are both non-toxic and can uniquely target malignant cells while ignoring healthy ones.“Cannabinoids … offer potential applications as anti-tumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival,” authors concluded. “[T]here is overwhelming evidence to suggest that cannabinoids can be explored as chemotherapeutic agents for the treatment of cancer.”"Read more: http://norml.org/news/2008/01/31/us-investigators-praise-cannabinoids-as-chemo-treatment
Marijuana=The Anti-Cancer Plant The cannabinoids in marijuana are powerful anti-cancer agents which work in many ways to suppress and destroy malignant cells. These actions are the dreams of cancer researchers and yet, marijuana remains illegal. Spread the news, using marijuana lowers your risk for developing cancer as well as diabetes and Alzheimer's disease!
Int J Oncol. 2012 Aug
.Cannabinoid-associated cell death mechanisms in tumor models review.Calvaruso G, Pellerito O, Notaro A, Giuliano M.SourceDepartment of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy.
Abstract: In recent years, cannabinoids the active components of Cannabis sativa and their derivatives have received considerable interest due to findings that they can affect the viability and invasiveness of a variety of different cancer cells. Moreover, in addition to their inhibitory effects on tumor growth and migration, angiogenesis and metastasis, the ability of these compounds to induce different pathways of cell death has been highlighted. Here, we review the most recent results generating interest in the field of death mechanisms induced by cannabinoids in cancer cells. In particular, we analyze the pathways triggered by cannabinoids to induce apoptosis or autophagy and investigate the interplay between the two processes. Overall, the results reported here suggest that the exploration of molecular mechanisms induced by cannabinoids in cancer cells can contribute to the development of safe and effective treatments in cancer therapy.